Recently, all three EASIX scores have been associated with the development of severe CRS and ICANS in patients who received C-type lectin-like molecule 1 CAR-T cell immunotherapy for acute myeloid leukemia [33]. Here, CLEC12A is linked to acute myeloid leukemia.